Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Co-Diagnostics, Inc. (CODX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.9700+0.3400 (+7.34%)
At close: 04:00PM EDT
5.0500 +0.08 (+1.61%)
After hours: 07:32PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.6300
Open4.6500
Bid5.0200 x 1400
Ask5.0000 x 1100
Day's Range4.6500 - 5.1800
52 Week Range3.6600 - 11.8200
Volume580,493
Avg. Volume342,551
Market Cap168.919M
Beta (5Y Monthly)-1.14
PE Ratio (TTM)3.79
EPS (TTM)1.3120
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
142% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for CODX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Co-Diagnostics, Inc.
    Weekly Stock ListESG Stocks
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Motley Fool

    Why Co-Diagnostics Trounced the Market on Thursday

    Investors took the measure of healthcare testing products specialist Co-Diagnostics (NASDAQ: CODX) and gave it an enthusiastic thumbs-up on Thursday: The company's stock closed the session more than 7% higher. The stock's upward move was propelled by fresh news from the company about its potential role in combating the latest potential global health threat. Thursday morning, Co-Diagnostics announced that it has leveraged its molecular diagnostics platform to finish the principal design work on a PCR test for monkeypox, a rare and occasionally deadly virus first detected in Southern Africa.

  • PR Newswire

    Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus

    Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the principal design work of a PCR test for the monkeypox virus currently exhibiting a multi-country outbreak.

  • PR Newswire

    Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 Global Investment Conference on May 23-26

    Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the H.C. Wainwright & Co. 2022 Global Investment Conference, being held in-person and virtually on May 23-26 in Miami, Florida.

Advertisement
Advertisement